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Abstract
Purpose of review The purpose of this review is to summarize current understanding
regarding the treatment of myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-
associated demyelination in children. Emphasis is placed on the unique obstacles we face
when predicting the risk of relapse and the important implications of such challenges
when planning treatment protocols.
Recent findings MOG-Abs are consistently identified in a range of acquired demyelinating
syndromes (ADS) in adults and children with a clinical phenotype distinct of MS and AQP4-
Ab neuromyelitis optica spectrum disorder. Although initially thought to be associated
with a benign disease, recent reports of children who are treatment-resistant and devel-
oped progressive disability over time raise important questions about how children with
relapsing MOG-Ab disease should be managed.
Summary MOG-Abs are common in children with ADS with both monophasic and relapsing
disease courses. Treatment of patients with MOG-Ab-associated demyelination includes
management of acute relapses and chronic immunotherapy for those with relapsing
disease. Emerging consensus supports distinction of treatment strategies from those
typically used for relapsing remitting MS, and several groups debate whether to follow
treatment protocols akin to those for AQP4-Ab NMOSD. A key challenge remains predicting
the severity of the disease at onset. Collaborative international consensus to derive shared
clinical evaluative platforms standardized biological and neuroimaging protocols which
can be used clinically, and partnered research programs are required to advance person-
alized treatment for children with MOG-Ab-associated demyelination.
Introduction
Themyelin protein,myelin oligodendrocyte glycoprotein
(MOG), is exclusively expressed in the central nervous
system (CNS). Although MOG represents only a minor
component (0.05%) of themyelin sheath, its location on
the outermost lamellae [1] and on the cell surface of
oligodendrocytes makes it highly immunogenic and
available for antibody binding [2]. In animal models,
antibodies identified following MOG induction appear
to mediate or contribute directly to demyelination [3].
Antibodies to MOG (MOG-Abs) have been detected
in 30–50% [2, 4] of children at first presentation of
acquired demyelinating syndrome (ADS) [5], with two
studies from the UK/France [4] and the Netherlands [6]
suggesting that MOG-Abs identified at onset are associ-
ated with a non-MS disease course. The presence of
MOG-Ab identifies a subset of adults [7–9] and children
[10, 11] meeting the clinical and imaging criteria for
neuromyelitis optica spectrumdisorder (NMOSD)with-
out antibodies to aquaporin-4. Identification of MOG-
Ab at the time of incident ADS, however, does not
predict risk of relapse, as the majority of MOG-Ab-
positive childrenwith acute disseminated encephalomy-
elitis (ADEM) or isolated optic neuritis (with normal
brain MRI) experience a monophasic disease course.
Published cohort studies of adults [7–9] and children
[10, 11] with NMOSD demonstrate that MOG-Abs asso-
ciated with younger patients (particularly children) are
frequently in males (and do not demonstrate the strong
female preponderance seen in AQP4-Ab NMOSD), and
despite the relapsing disease course, patients demonstrate
good recovery from the acute relapses and the overall
visual and motor outcome is better compared with
AQP4-Ab-positive patients [12, 13].
A proportion of patients with MOG-Abs meet the
McDonald 2017 criteria for a diagnosis of MS at onset
and can experience relapses typical of MS posing signif-
icant diagnostic and treatment challenges. Features of
such patients that render them “atypical” for MS will be
presented.
Treatment of patients with MOG-positive demyelin-
ation includes management of acute relapses and chronic
immunotherapy for those with relapsing MOG disease.
Emerging consensus supports distinction of treatment
strategies from those typically used for relapsing remitting
MS, and several groups debatewhether to follow treatment
protocols akin to those for AQP4-Ab NMOSD [14, 15].
In this review, we will focus on pediatric-onset MOG-
Ab-associated disease, with specific attention to challeng-
ing clinical scenarios. We will review data on the acute care
of a demyelinating attack in addition to treatment of
patient with relapsing diseases. Particular attention will
be paid to the unique obstacles we face when predicting
the risk of relapse and the important implications of such
challenges when planning treatment protocols.
Part 1: In clinical practice
Presenting features
The clinical phenotypes of children with MOG-Ab-associated disease include
monophasic ADEM, ADEM followed by recurrent optic neuritis (ON), or AQP4-
negative NMOSD [11]. MOG-Abs are present in more than 30% of children who
present with an initial episode of demyelination, in more than 50% of those
presentingwith ADEM, and in almost all thosewithmultiphasic ADEM (MDEM)
[16]. The prevalence of MOG-Ab stratified to the different demyelinating phe-
notypes is summarized in Table 1. Children with MOG-Ab are frequently Cau-
casian (in contrast to patients with AQP4-Ab who are more often non-Cauca-
sians). In younger children, males are equally represented, with a slight female
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preponderance in adolescents (in contrast with the marked female preponder-
ance seen in AQP4-Ab patients). Unlike AQP4-Ab-positive NMOSD, MOG-Ab
does not link with other autoimmune diseases and was not reported in associa-
tion with specific malignancy. Although many patients report prodromal ill-
nesses, no specific viruses have been linked to MOG-related demyelination.
MOG-Ab autoimmunity is not only more common in the young, but also
appear to demonstrate age-dependent phenotypes, with brain involvement
more frequently seen in younger children and ON and NMOSD in the older
children (9 9 years) [21] and adults [22•].
Overall, in pediatrics, MOG-Abs are more common than AQP4-Ab. In chil-
dren with ON, in whom about 50% will have MOG-Ab, involvement of the
anterior optic pathway (papillitis) is more frequently seen as compared to AQP4-
Ab-positive patients who more often have lesions involving the posterior path-
way with both chiasmal and post chiasmal involvement [23]. In both MOG-Ab-
and AQP4-Ab-related demyelination, bilateral ON and the presence of longitu-
dinally extensive lesions extending down the optic pathway are distinguishing
features, as these are atypical for isolated ON or for optic nerve relapses in MS.
Interestingly, MOG-Abs are uncommon in children presenting with isolated
TM. In a recent report of 50 children with TM, only 3 (6%) were MOG-Ab-
positive [16]. 39/50 (78%) who presented with TM were antibody-negative,
and 36/50 (72%) experienced a monophasic disease course. The rare child who
experiences relapsing TM typically either meets criteria for a diagnosis MS based
on brain lesion pattern and non-spinal cord relapses or meets criteria for
NMOSD (with antibodies to AQP4 or MOG). MOG-Ab-positive TM is almost
always consistent with LETM, with central cord lesion involving the nerve roots
and gray matter [24]. T2-bright lesions can extend all the way from the cervical
spinal cord to the conus [25]. In contrast, in AQP4-Ab-positive patients spinal
lesions are frequently in the cervico-thoracic spine andmay extend superiorly to
the brainstem (area postrema), while spinal lesions in MS are focal (G 3 spinal
segments) and rarely traverse the full cross-sectional diameter of the cord [26].
When brain lesions are present identification of specific pattern may aid in the
diagnosis, for example, when the brain lesions are typical for MS.
In general, MOG-Ab and AQP4-Ab patients differ in terms of clinical severity at
onset, with a milder deficit in the MOG-Ab group [22, 27]. For example, MOG-Ab
patients with T2 bright signal involving the entire spinal cord may have relatively
mildweakness and sensory impairment and recover promptly and completelywith
acute treatment. This is in keeping with historical reports of children with ADEM
(who were likely to have MOG-Ab) andmyelopathy onMRI with no clinical signs
to support the myelopathy. Despite the milder motor phenotype at onset, it is
important to monitor for bowel and bladder problems at follow-up with a recent
adult cohort reporting 28% bladder issues, 20% bowel dysfunction, and 21% of
males had erectile dysfunction; all related to a previous transverse myelitis [27].
MOG-Abs are detected in over half the children presenting with ADEM and in
nearly all patients who relapse following ADEM (MDEM, ADEM-ON, and
NMOSD) [16, 17•, 20•]. No clinical features or brain MRI findings, at onset of
ADEM, can distinguish between the MOG-Ab positive and ADEM without
antibodies. Although initially thought to be associatedwith predominantly white
matter disease, there are increasing reports of both adults [28, 29] and children
[30••] with MOG-Ab-associated disease presenting with predominantly gray
matter disease (some may have MRI findings restricted to the cortex) presenting
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with encephalopathy and seizures. Children presenting with a clinical phenotype
of encephalopathy, seizures, and headaches associatedwith focal leptomeningeal
enhancement have been diagnosed CNS vasculitis [30••]. Brain biopsies in some
of these children support such a diagnosis, and many of the prior studies were
reported prior to the ability to measure MOG-Ab [31].
Part 2: Investigations
Antibody detection assay
The different antibody detection methods are now an essential laboratory
investigation in evaluating children with inflammatory CNS disorders, with
diagnostic, prognostic, and therapeutic implications. Interpreting these assays
requires the knowledge of themethodological strengths andweaknesses of each
technique and is different for the different antigens identified (intracellular vs.
extracellular). Earlier studies, which looked at antibodies to the linear epitopes
of the denatured MOG protein using ELISA and Western blotting, resulted in
inconsistent results and positivity in healthy controls [32]. Additionally, even
when using the more specific cell-based assays, differences in positivity across
cohorts were seen when the full-length protein construct is used, compared to
the truncated form that lacks the intracellular domain. The reason for this
difference is unknown, but recent studies suggest that the full-length protein can
provide a specific and more sensitive assay for antibodies to MOG in patients
with demyelinating disorders. Another technical obstacle with the MOG assay
was the cross-reactivity of the IgG heavy and light secondary antibody with
MOG-IgM and the need to use either specific IgG1 secondary antibody [33] or a
secondary anti-Fc. To date, no comparative study to compare the sensitivity and
specificity of these twomethods has been performed, but both assays appear to
identify patients with similar MOG-Ab phenotypes.
The relationship betweenMOG-Ab titers and clinical disease activity, however,
remains an area of active investigation, with a recent report suggesting that a high
MOG-Ab titer (≥ 1:1280) predicted a recurrent non-MS course with a sensitivity of
46% and a specificity of 86% [17•]. The presence of MOG-Ab over time, however,
does not reliably predict relapses, as shown by a study demonstrating that persis-
tence in antibody positivity in 35/43 (81%) of children did not differentiate
between monophasic and relapsing patients (13/16 monophasic and 22/27 re-
lapsing were persistently positive) [16]. Interestingly, two children with relapsing
ADEM became seronegative in between attacks and were MOG-Ab-positive at the
time of relapse. None of the children were MOG-Ab-negative at time of relapse. A
large nationwide French study of 197 adults with MOG-Ab [22•], observed that
the titters were higher at relapse than in remission, but only two patients (18.2%)
became seronegative. Overall, the authors concluded that antibody titers were not
reliable enough to use in the clinical setting for patient management.
Neuroimaging
Neuroimaging studies in MOG-Ab patients should include the entire spine, optic
nerves (if visual symptoms), and the brain. When present, T2 bright brain lesions
typically involve white matter tracts, or can demonstrate large, hazy, ill-defined
white matter lesions, and often involve deep gray matter (most commonly the
thalamus) [24]. Imaging can usually be distinguished from MS by the absence of
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discrete, well-defined oval lesions in the periventricular white matter. Figure 1
illustrates some of the imaging patterns seen in children with MOG-Ab-associated
disease. Children with MOG-Ab may present with four MRI patterns: (1) multi-
focal hazy/poorlymarginated lesions, involving both graymatter andwhitematter
and typically involving the middle cerebellar peduncles; (2) spinal cord and/or
optic nerve involvement with normal intracranial appearance, or non-specific
white matter lesions; (3) extensive and periventricular white matter lesions, re-
sembling a “leukodystrophy-like” pattern; and (4) cortical encephalitis with
leptomeningeal enhancement. Dramatic resolution, sometimes within amonth of
presentation, has been the radiological hallmark of MOG-Ab, perhaps suggesting
that there is more edema than demyelination. Nevertheless, a proportion of
children (predominantly very young patients) develop a “leukodystrophy-like”
phenotype with large confluent lesions and significant brain atrophy mimicking a
neurodegenerative disease [21]. Enhancement pattern can also aid in the diagnosis
with ring/broken ring enhancement inMS [34], cloud-like enhancement in AQP4-
Ab [35] and highly contrast enhancing lesion in the “leukodystrophy-like” phe-
notype [21]. This contrast enhancement may persist overtime even outside of a
clinical attack.
Optical coherence tomography
Optical coherence tomography (OCT) and electrodiagnostic tests can be useful
paraclinical parameters in patients with ON [36•]. OCT quantifies retinal nerve
fiber layer (RNFL) and ganglion cell layer thinning, and the development of
microcystic macular edema and retinal damage. OCT offers an opportunity to
monitor disease activity and progression non-invasively.
Part 3: Clinical outcomes
The accumulation of disability in patients with antibody-mediated diseases, such
as MOG-Ab, is thought to be very specifically relapse-related. Given the risk of
disability due to incomplete relapse recovery, identifying patients at risk for
relapse, and treating those with relapses, is the main focus of current manage-
ment. Importantly, whileMOG-Ab patients can experience a chronic disease with
multiple relapses, some children experience a single event with a biphasic
presentation (as defined by re-emergence of prior symptoms or expression of
new symptoms within 90 days of initial presentation or at the time of weaning
corticosteroids). Management of these two patient groups is clearly different.
Relapses following ADEM as defined by the International Pediatric Multiple
Sclerosis Study Group (IPMSSG) revised criteria [37] may manifest as (i)
recurrence of neurological symptoms within 3 months, often as immuno-
modulatory treatment is being weaned, considered to be a single protracted
ADEM episode; (ii) second episode of ADEM after 3 months defined as “mul-
tiphasic” (MDEM) where there is either re-emergence of previous neurologic
symptoms or new and different signs and magnetic resonance imaging (MRI)
findings; or (iii) second clinical event is not associated with encephalopathy or
occurs three or more months after the incident neurologic event [38].
Just as it is true in the clinical course, the radiological progression over time
is different for the different syndromes with accrual of new focal lesions in MS
(both symptomatic and clinically silent lesions) and symptomatic lesions only
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Fig. 1. MRI findings in children with MOG-Ab-associated disease. A 10-year-old boy presented with encephalopathy, limb weakness
(but able to walk), bilateral optic neuritis with only light perception, and urinary incontinence. MRI revealed longitudinally
extensive transverse myelitis (a) and bilateral optic neuritis with enhancement (b). He relapsed 4 months later with headaches,
fever, and encephalopathy. MRI revealed confluent lesions involving the pons, midbrain, and the superior cerebellar peduncles (c)
as well as the left frontal opercular cortex. The previous spinal lesion has significantly improved (d). A 4-year-old girl presented with
encephalopathy, seizures, and lethargy progressed to weakness of her right arm and bilateral 6th nerve palsies. MRI demonstrated a
focus of signal change in the right thalamus (e). She relapsed 4 months later with brainstem cerebellar syndrome and lesions in both
middle cerebellar peduncles (f) as well as a new lesion in the left side of the midbrain (not shown). At 4 years of age, she presented
with bilateral optic neuritis. MRI showed diffuse bilateral white matter signal abnormality involving the cortical and subcortical
regions extending inferiorly along the cerebral peduncles, pons, and right middle cerebellar peduncle, as well as swelling and signal
abnormality of the corpus callosum (g). She had a further episode of bilateral optic neuritis 1 year later. A 4-year-old girl presented
with encephalopathy, headache, and lethargy and MRI findings revealed diffuse bilateral and asymmetric signal abnormalities of
the basal ganglia and thalamus with similar non-enhancing disease of the cortex, subcortical and deep white matter of both
hemispheres (h). Repeat imaging 3 months later demonstrated near complete resolution of all lesions, concurrent with clinical
recovery. She relapsed 15 months later with new onset headaches, encephalopathy characterized by behavioral change with
hallucinations and confusion, and MRI evidence of new cortical and juxtacortical T2 lesions (j).
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at time of clinical relapses in patients with AQP4-Ab NMOSD and MOG-Ab-
associated demyelination, with significant resolution of the lesions in follow-up
scans. Radiological evolution ofmyelitis (from short myelitis to LETM) over the
first 12 days from presentation in a patient with AQP4-Ab NMOSD highlights
that consideration of the timing of imaging is key and the time point to
radiological nadir may be variable [39]. Radiological lag with worsening of the
MRI during clinical recovery can be seen in children with MOG-Ab. This is also
important to take into account at the time of follow-up scan; the first follow-up
scan may not be suitable in identifying accrual of new lesions as the initial scan
was only taken at one time point of a more dynamic process.
Part 4: How to treat?
Acute management
Currently, there are no evidence-based guidelines for the acute treatment of chil-
dren with MOG-Ab. The current treatment approach typically focuses on removal
of the systemic antibodies and immunosuppression. Of note, time from symptom
onset to acute treatment in AQP4-Ab NMOSD is one of the major predictors of
long-termoutcome, as evidenced by a recent study of 29 adult patients with AQP4-
Ab NMOSD, identifying an inverse correlation between the delay time pre-PLEX
and EDSS score at 6-month post onset. Furthermore, the percentage reductions in
EDSS score in groups receiving PLEX on days ≤ 15 and days 16 to 30 were
significantly greater than those in the groups treated on days 31 to 60 and days 61
to 90 (all, P G 0.05) [40]. Although two large retrospective studies in adults [22•,
41] and one small retrospective study in children with MOG-Ab and ON [42]
demonstrated favorable visual outcome, patients with MOG-Ab canmanifest with
severe visual loss and permanent paresis or ataxia [43]. A more aggressive, treat-
ment-resistant, disease course may be seen in younger children in view of the
increase susceptibility of the myelinating brain to MOG-Ab disease, as the
autoantibody-mediated damage to the not fully matured (uncompact myelin)
may result in secondary damage and irreversible axonal loss [44].
First-line immunotherapy normally consists of intravenous corticosteroids
(30 mg/kg/day, maximum 1 g for 3–5 days), IVIG (total of 2 g/kg over 2 or
5 days), and plasma exchange (PLEX) in isolation or combination. PLEX with
five to seven exchanges on alternative days is the best way of reducing antibody
levels if urgently required, but not all centers will have the facilities. In pediatric,
the tolerability of PLEX may also depend on the age and clinical presentation;
an encephalopathic child with ADEM is less likely to tolerate plasma exchange
than a teenager with transverse myelitis who is paralyzed. The sequence in
which these therapies are given is also important as giving IVIG followed by
plasma exchange will remove the IVIg from the systemic circulation. Steroids
(intravenous methylprednisolone and/or high dose oral prednisolone) are
thought to be very useful in reduction of inflammation, sealing of the blood
brain barrier, and overall reduction of antibody production. Many of the
patients with MOG-Ab, particularly the ones with abnormal brain MRI, have
CSF leucocytosis and may initially be diagnosed as viral encephalitis [5, 30••].
Although corticosteroids were originally avoided in patients in whom the
diagnosis of viral infection cannot be ruled out, evidence that corticosteroid
administration with concurrent antibiotics/antiviral reduces neurological dis-
ability in immunocompetent children with various forms of CNS infections
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[45, 46] reduces concern regarding safety of corticosteroids acutely while the
antibody results are pending.
The decision for how long to wean the corticosteroids for is dependent on
the severity of the attack. With the clinical overlap between MOG and AQP4
antibody-associated diseases, many clinicians would not reduce the oral pred-
nisolone below 20 mg per day (in the absence of maintenance immunosup-
pression) when the diagnosis of AQP4-Ab NMOSD is being considered.
Therefore, as inmost center the time to antibody results may take up to 3 weeks,
many of the children (particularly the one presenting with optic neuritis or
transverse myelitis) remain on steroids for over 4–6 weeks at the initial pre-
sentation. Chronic administration of corticosteroids has adverse effects on
muscle, bone, mood, and the endocrine system and steroid-sparing medica-
tions might need to be considered if patients have repeated episodes when
tapering of steroids is attempted. An association between post corticosteroids
hypocortisolismwith early first relapse was previously reported in children with
idiopathic nephrotic syndrome with adrenocortical suppression being more
common in younger children [47]. As the disease process in both nephrotic
syndrome and MOG-Ab-associated disease is sensitive to glucocorticoid med-
ication, differences in endogenous secretion of cortisol following prolonged
treatment may be critical with younger children, perhaps more sensitive to the
suppressive effect of prednisone when the dose is calculated per weight. This
may result in iatrogenic relapses following weaning of medication.
Maintenance treatment for relapse prevention
Figure 2 illustrates a treatment algorithm for children with MOG-Ab. Following
standard acute/induction therapy, a decision regarding the need for ongoing
therapy for relapse prevention is typically influenced by (i) the likelihoodof relapse
or if more than one event time to relapse or annual relapse rate, (ii) the response to
first-line treatment, and (iii) the severity of attack and the recovery from the initial
attack. For example, if the child’s vision is poor in one eye, further relapse in the
same eye or in the other eyemay have a significant effect on the child disability and
quality of life. In a study of 102 children with MOG-Ab-associated relapsing
disease, only 52/102(51%) receivedmaintenance treatment. The treated grouphad
higher relapse rate and EDSS than the untreated group (median 1 relapse andEDSS
1.0 in the untreated group). This treatment paradoxwhereby the higher relapse rate
and poorer outcome in the group havingmore therapy is simply reflected by the a-
priori threshold for initiating such treatments. Nevertheless, these results suggest
that at least a proportion of children may not require maintenance treatment.
Several case series advocate that typical first-line chronic MS treatment
(interferon, glatiramer acetate) do not suppress relapses in MOG-Ab disease
[30••, 48].
Despite the logic of using B cell depletion as a strategy for an antibody-
associated disease, there are now increasing reports of patients with MOG-Ab
who relapse on rituximabdespite B cell depletion [30••]. In a study of 102 children
with MOG-Ab-associated diseases, relapses were reported on all treatments (my-
cophenolatemofetil, azathioprine, rituximab, and cyclophosphamide) [30••]. The
only treatment that appears to prevent relapses, particularly in children with
multiple relapses a year, is repeated IVIG (every 4weeks). IVIG is the only treatment
that modifies the disease without leading to immunosuppression and risk of
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Fig. 2. Treatment algorithm for children with MOG-Ab-associated disease. IVMP intravenous methylprednisolone, PLEX plasma
exchange, IVIG intravenous immunoglobulin, AZA azathioprine, MMF mycophenalate mofetil.
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infection-triggered relapses. Interestingly, in a recent study using organotypic cere-
bellar slice cultures from transgenic mice and MOG-Ab-induced demyelination,
IVIG was protective from demyelination in a dose-dependent manner. As binding
to MOG antibody was not prevented, it was hypothesized to result from interfer-
ence to complement-mediated oligodendroglial damage [49].
In cell culture, incubation with purified IgG from anti-MOG antibody-positive
patients led to loss of the microtubule cytoskeleton of oligodendrocytes [19], and
injection of purified IgG into the brains of mice resulted in myelin changes and
altered expression of axonal proteins in the absence of inflammation, axonal loss,
andneuronal or astrocyte death [50]. This evidence suggestsMOGantibodies result
in an autoimmune oligodendrogliopathy [51]. More generally, in antibody-
mediated disorders, upregulation in the Th17 pathway, with raised CSF IL6, has
been more commonly noted—a finding that is rare in MS [52].
One of the explanations for the heterogeneity in treatment response is that
the MOG-Ab-specific damage is induced by multiple pathogenic mechanisms.
A recent study looking at the effect of these antibodies in a T cell-mediated EAE
animal models identified two pathogenicmechanisms both requiring specific T
cell lines to cause the clinical disease [53]. (1) In synergy with MBP-specific T
cells, patients derived MOG-Ab-induced active demyelination as seen in type 2
MS pathology (actively demyelinating lesions with loss of all myelin compo-
nents, and immunoglobulin and complement deposition on the myelin) as-
sociated with profound blood brain barrier damage, activation of macrophages
and local activation of terminal complement, an effect which was not seen with
the T cells alone. (2) In synergy with cognate MOG-specific T cells, which by
themselves do not induce clinical disease, the same affinity purified MOG-Ab
preparation induced massively enhanced T cell infiltration and stimulation of
microglia/macrophage infiltration in the subpial gray matter. It is not clear if
these mechanisms affect all patients, occur at different stages of the disease or
mediate different relapses, but these findings may suggest that targeting the
antibody production alone may not be enough to stop the disease. Further
studies on genetic susceptibilities, environmental triggers, and the role of the
MHC complex in association with specific T cells may help in developing
personalized medicine for children with MOG-Ab-associated disease.
Part 5: Future directions
Meaningful advances in the diagnosis, prognostication, and treatment ofMOG-
Ab-positive patients requires a collaborative international consensus to derive
shared clinical evaluative platforms, standardized biological and neuroimaging
protocols which can be used clinically, and partnered research programs. Im-
munological signatures overtime may help when deciding on both treatment
choices (targeting T cells vs B cells) and treatment duration. Consistent evalu-
ation of patient outcomes is essential, but current outcome measures, such as
the EDSS, used both clinically and for research, are not sufficiently sensitive.
A key challenge in selecting a suitable outcomemeasure. For younger MOG-Ab
patients with an ADEM phenotype, cognitive evaluations are likely to be particu-
larly informative. For MOG-Ab NMOSD, evaluation of visual function (including
low contrast acuity, visual processing speed, and retinal nerve integrity) as well as
gait assessment and evaluation of bladder function are more relevant. Inherent to
Curr Treat Options Neurol (2019) 21: 2 Page 11 of 14 2
the study of pediatric-onset disease, the full impact may not be immediately
detected and may become more apparent as the child ages and fails to normally
develop pathways that were injured during the acute phase of their illness.
The opportunity for early immunosuppressive treatment must be weighed
against the potential to provide such therapy to a child destined for a
monophasic illness for whom such prompt treatment is not required. At the
present time, MOG-Ab titers, even when measured serially, do not reliably
inform on such decisions. Future research will be invaluable in determining the
immunological signatures that better identify children who require sustained
immunosuppression. International collaborationwill accelerate such discovery.
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